Member Info for Hurst10

Nice buy tickets pre and post the close will lift the price swiftly higher

Inteteresting!

Seems that no option trade in Avacta is possible at the moment.

Affyxell listing will provide a “Pre IPO research” always very friendly, as one would expect!

Another thing to remember is that once the Affyxell Mesenchymal Stem Cell story takes off properly, with more press coverage, research coverage etc., the IPO story will take off again, with a revised valuation and an subsequently an interesting value applied to Avacta’s nil cost holding!

Speaking of Novartis, prior to joining Avacta Dr.Christina Coughlin now Non Executive Director at Avacta and speaking at the ISCT conference, was also Executive Director of Oncology clinical development at Novartis!

Tomorrows session 1.18.30-20.30( excellent for US hrs) Messenchymal Stem/Stromals.so far from Affyxell’s website :

“ DW-MSC is an advanced platform technology capable long-term cultivation compared to conventional tissue-derived mesenchymal stem cell”

From their Website:

Stem cell therapeutics platform (DW-MSC) of Daewoong Pharmaceuticals is advanced stem cell platform technology that has overcome current limitations of tissue-derived mesenchymal stem cell. For therapeutic functional improvement through the introduce gene of stem cell, a stem cell must possible to long-term cultivation. DW-MSC is an advanced platform technology capable of long-term cultivation compared to conventional tissue-derived mesenchymal stem cell and mass production of cell & gene therapeutic with highly consistent quality after introduction of therapeutic gene.

In the past the company had a research lab in Cambridge and I used to say, Avacta is the best thing out of Cambridge since Arm Holdings!

+ worth bearing in mind that Dr. William Tap of Memorial Sloan Kettering Cancer Center will no doubt be attending ASCO and attract media interest.

To discuss technical analysis, dead cross, MAV ect, I am afraid is not relevant.

Biotech have stocks purely driven by news flow or the lack of it.

In this case we have upcoming news event which will change future of the company and if we are lucky, will not be acquired too early!!

Apart from a share sale years ago to complete a house purchase, no director have ever disposed of any significant amount of shares.The incoming inflow of directors joining at very senior level are the lucky ones with packages full of options etc.If you are patient enough you will have a company, that will show Nasdaq why British biotech attracts such talent and they will all say “ do you remember when Avacta was trading 110” when it will be trading at 10x current level and you have a Diagnostic company as well.Good luck

With our upcoming two weeks of news flow and events and M&A continuing state side in front of ASCO,worth remembering that at ISCT we have Affyxell releasing latest data and Avacta’s non Executive director Christina Coughlin participating at a panel discussion. She is ex Pfizer and Novartis.

+50/ after hrs.

More of this to come .

Clever purchse!

As you can see M&A activity is taking off on a daily basis, valuations going north and all eyes will be on ASCO conference, the OSCAR’s of Biotech.Look what happen to Avacta’s share price last year post confernce.

Stand by for more Cohort news as well!

Watch out for more post hours size prints!!

Remember we have ISCT conference in Paris first,31/5-3/6 with Affyxell presenting.Stemcell valuations is going north fast.

More M&A in the ADC area.

Pyxis Oncology positioned at forefront of Antibody-Drug Conjugate (ADC) development

Commercially and clinically validated APXiMAB platform for antibody generation complements FACT ADC toolkit of linkers, payloads and conjugation chemistries previously obtained from Pfizer

Sotigalimab, a potential best-in-class Phase 2 CD40 agonist, has demonstrated rapid, deep and durable responses across difficult-to-treat tumor types

All-stock deal allows Pyxis Oncology to maintain cash runway into 1H 2025;

PYX-201 and PYX-106 remain on track

Webcast to be held today, May 24, at 9:00 a.m. ET

BOSTON and SAN CARLOS, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (“Pyxis Oncology”) (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, and Apexigen, Inc. (Nasdaq: APGN), a clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody therapeutics for oncology, today announced a definitive agreement by which Pyxis Oncology will acquire Apexigen in an all-stock transaction for an implied value of $0.64 per Apexigen share. For each share of Apexigen, Pyxis Oncology will issue 0.1725 shares of its common stock, par value $0.001 per share, for a total enterprise value of approximately $16 million.

Apologies if already printed.

Worth remembering that we have got ISCT conference in Paris 30/5-3/6 2023.

We should also have data being presented by companies attending such as Affyxell( Avacta ) and Christina Coughlin MD of Cytoimmune Therapeutics being guest speaker at a panel, discussing “ Tackling Challenges in Cell Therapy for Solid Tumors”.

Excellent timing for Avacta pre ASCO!

AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million

All-cash transaction, with full $87.5 million to be paid at closing

Proceeds expected to extend cash runway into Q4 2024

May 22, 2023 07:00 AM Eastern Daylight Time

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced an agreement to sell its investigational hematopoietic stem cell (HSC) gene therapy program for the treatment of cystinosis to Novartis for $87.5 million in cash. AVROBIO retains full rights to its portfolio of first-in-class HSC gene therapies for Gaucher disease type 1 and type 3, Hunter syndrome and Pompe disease. Proceeds from this transaction are expected to extend the Company’s cash runway into the fourth quarter of 2024. “This transaction strengthens AVROBIO’s balance sheet, focuses our pipeline strategy and is a strong endorsement of our HSC gene therapy approach and plato® gene therapy platform,” said Erik Ostrowski, AVROBIO’s interim CEO and current CFO.

CRISPR-Mediated Correction of ABCA4 Mutations in Stem Cells May Provide Treatment for Incurable Inherited Disease Causing Vision Loss

In a recent study, researchers in Spain confirmed the feasibility of using CRISPR-Cas9 to correct pathogenic mutations in the ABCA4 gene in patient-derived stem cells, providing proof-of-concept evidence that gene and cell therapies may provide a treatment method for inherited retinal dystrophies.

Possible to have the link open, cannot access it.

Thx

Bring on Monday

ASGCT News: David Liu Hails Rapid Progress in Precision Genome Editing

In an exemplary keynote address, the developer of base and prime editing salutes the rapid uptake of “CRISPR 2.0” editing technologies around the world, as indicated by a succession of encouraging preclinical studies.

More M&A in gene therapy

SPAC Forbion European Acquisition Corp. (NASDAQ:FRBN) has agreed to merge with Canadian biotech enGene, a developer of non-viral gene therapies.

Pre ASCO this will continue!

Cohort 6 to start ?

Size buying before the close.

Post hours prints?

So far only LEGO